Literature DB >> 27683045

MELAS Syndrome and Kidney Disease Without Fanconi Syndrome or Proteinuria: A Case Report.

Michael Rudnicki1, Johannes A Mayr2, Johannes Zschocke3, Herwig Antretter4, Heinz Regele5, René G Feichtinger2, Martin Windpessl6, Gert Mayer7, Gerhard Pölzl8.   

Abstract

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS syndrome) represents one of the most frequent mitochondrial disorders. The majority of MELAS cases are caused by m.3243A>G mutation in the mitochondrial MT-TL1 gene, which encodes the mitochondrial tRNALeu(UUR). Kidney involvement usually manifests as Fanconi syndrome or focal segmental glomerulosclerosis. We describe a patient with MELAS mutation, cardiomyopathy, and chronic kidney disease without Fanconi syndrome, proteinuria, or hematuria. While the patient was waitlisted for heart transplantation, her kidney function deteriorated from an estimated glomerular filtration rate of 33 to 20mL/min/1.73m2 within several months. Kidney biopsy was performed to distinguish decreased kidney perfusion from intrinsic kidney pathology. Histologic examination of the biopsy specimen showed only a moderate degree of tubular atrophy and interstitial fibrosis, but quantitative analysis of the m.3243A>G mitochondrial DNA mutation revealed high heteroplasmy levels of 89% in the kidney. Functional assessment showed reduced activity of mitochondrial enzymes in kidney tissue, which was confirmed by immunohistology. In conclusion, we describe an unusual case of MELAS syndrome with chronic kidney disease without apparent proteinuria or tubular disorders associated with Fanconi syndrome, but widespread interstitial fibrosis and a high degree of heteroplasmy of the MELAS specific mutation and low mitochondrial activity in the kidney.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fanconi syndrome; Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS syndrome); focal segmental glomerulosclerosis (FSGS); heteroplasmy; kidney biopsy; proteinuria; renal

Mesh:

Year:  2016        PMID: 27683045     DOI: 10.1053/j.ajkd.2016.06.027

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

1.  MELAS syndrome with rare manifestations misdiagnosed as vasculitis in the absence of lactic acidosis: A case report.

Authors:  Mohammad Alsultan; Deema Alshaar; Badie Alkhouli; Qussai Hassan
Journal:  Ann Med Surg (Lond)       Date:  2022-08-27

2.  A case report of mitochondrial myopathy with membranous nephropathy.

Authors:  Minchao Cai; Qing Yu; Jinfang Bao
Journal:  BMC Nephrol       Date:  2022-03-04       Impact factor: 2.388

Review 3.  The Vicious Cycle of Renal Lipotoxicity and Mitochondrial Dysfunction.

Authors:  Mengyuan Ge; Flavia Fontanesi; Sandra Merscher; Alessia Fornoni
Journal:  Front Physiol       Date:  2020-07-07       Impact factor: 4.566

4.  Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus.

Authors:  Maaike C De Vries; David A Brown; Mitchell E Allen; Laurence Bindoff; Gráinne S Gorman; Amel Karaa; Nandaki Keshavan; Costanza Lamperti; Robert McFarland; Yi Shiau Ng; Mar O'Callaghan; Robert D S Pitceathly; Shamima Rahman; Frans G M Russel; Kristin N Varhaug; Tom J J Schirris; Michelangelo Mancuso
Journal:  J Inherit Metab Dis       Date:  2020-02-07       Impact factor: 4.750

5.  Mitochondrial Disease (MELAS Syndrome) Discovered at the Start of Pregnancy in a Patient with Advanced CKD: A Clinical and Ethical Challenge.

Authors:  Domenico Santoro; Gianluca Di Bella; Antonio Toscano; Olimpia Musumeci; Michele Buemi; Giorgina Barbara Piccoli
Journal:  J Clin Med       Date:  2019-03-04       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.